Building materials group CRH agrees historic $8.5bn deal for Arcosa
CRH has agreed to acquire building materials group Arcosa for $8.5bn in what is described as a historic deal. The acquisition adds Arcosa's ~$4.7bn revenue base to CRH's $37.4bn, but the price premium and integration risk create a clear setup for divergent reactions in both stocks.
What happened
CRH has agreed to acquire building materials group Arcosa for $8.5bn in what is described as a historic deal.
The read · Jun 22
CRH's $8.5bn bet on ARCO raises the question of whether the premium is justified by infrastructure upside or whether thin acquired margins dilute CRH's returns profile.
Wrong if
A deal walk or regulatory block collapses ARCO sharply and removes the short-CRH pressure; alternatively, if CRH finances the deal with minimal equity dilution and strong synergy guidance, CRH could rally and close the pair against you.
CoverageSource: Financial Times · Published here MON, JUN 22 · 4:36 PM ET · the only report in this recordHow this is decided →
The chart · CRHTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
CRH has struck an $8.5bn deal to acquire Arcosa, a Dallas-based building materials company with $4.7bn in FY2025 revenue and exposure to infrastructure aggregates, engineered structures, and construction products. The deal size is notable — roughly 1.8x Arcosa's annual revenue — and comes as CRH has been aggressively repositioning its portfolio following its 2023 NYSE re-listing. CRH itself generated $37.4bn in revenue with a 10.1% net margin, suggesting meaningful scale advantages if integration executes cleanly.
The key tension is whether CRH is overpaying for a business running at a thin 4.5% net margin, or whether it is acquiring infrastructure-levered assets at a cyclical trough ahead of US infrastructure spending tailwinds. Arcosa shareholders will watch the deal premium carefully; CRH shareholders will focus on dilution math and whether the acquired margin profile drags on CRH's consolidated returns. The next catalysts are deal financing details and any analyst price-target revisions on CRH.
The read, in fullWhy it matters
Classic M&A pair: ARCO should re-rate to deal price (capturing premium), while CRH faces short-term pressure on dilution concerns given Arcosa's 4.5% net margin versus CRH's 10.1%. The deal at ~1.8x revenue for a thin-margin business raises legitimate overpayment risk for CRH equity. Long ARCO / short CRH captures the spread compression that typically follows large acquisition announcements.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
2-4 weeks into post-announcement price discovery. Follow to be told when one lands.
▲ The case it holds
ARCO shareholders capture a significant control premium — at $8.5bn on $4.7bn revenue, the deal likely represents a substantial uplift to ARCO's pre-announcement market cap, with limited downside unless the deal breaks.
▼ The case it breaks
CRH is absorbing a business with a 4.5% net margin (less than half its own 10.1%) at a rich revenue multiple, which risks dragging consolidated returns and invites near-term multiple compression on CRH shares.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →